Profound Medical (PROF) EBITDA Margin (2024 - 2026)

Profound Medical's EBITDA Margin history runs 3 years deep, the most recent figure standing at 150.98% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 25424.0% year-over-year to 150.98%; the TTM figure through Mar 2026 stood at 200.52% (up 9798.0% YoY), while the FY2025 annual figure was 250.26%, up 3662.0% from the prior year.
• EBITDA Margin was 150.98% for Q1 2026 at Profound Medical, down from 132.17% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 132.17% in Q4 2025 to a low of 587.16% in Q2 2025.
• Historically, EBITDA Margin has averaged 317.33% across 3 years, with a median of 345.44% in 2024.
• The sharpest annual moves came in 2025 and 2026: EBITDA Margin tumbled 20881 bps in 2025, then soared 25424 bps in 2026.
• A 3-year view of EBITDA Margin shows it stood at 165.59% in 2024, then increased by 20 bps to 132.17% in 2025, then retreated by 14 bps to 150.98% in 2026.
• The last three EBITDA Margin figures came in at 150.98% (Q1 2026), 132.17% (Q4 2025), and 166.1% (Q3 2025), per Business Quant data.